View Older Stories
-
Bausch & Lomb (BLCO) Reiterated at Hold by Stifel: Concerns About Execution
-
Bausch + Lomb refinances $2.8 billion in debt with lower rates
-
Bausch + Lomb adds two directors to board effective January 2026
-
Bausch + Lomb plans $2.8 billion loan refinancing to cut interest rates
-
Needham Reiterates Hold Rating on Bausch & Lomb Corp. (BLCO)
-
Bausch & Lomb Corp. (BLCO) PT Raised to $19 at RBC Capital
-
Bausch & Lomb Corp. (BLCO) PT Raised to $20 at Jefferies
-
Bausch + Lomb sets three-year growth targets at investor day
-
Needham Reiterates Hold Rating on Bausch & Lomb Corp. (BLCO)
-
Bausch + Lomb Corporation (BLCO) Tops Q3 EPS by 2c
-
Stifel Reiterates Hold Rating on Bausch & Lomb Corp. (BLCO); Says Cautious on New Market Execution
-
Goldman Sachs Starts Bausch & Lomb Corp. (BLCO) at Neutral
-
Bausch & Lomb Corp. (BLCO) PT Raised to $13 at BofA Securities
-
Bausch & Lomb Corp. (BLCO) PT Raised to $16 at H.C. Wainwright
-
Bausch + Lomb Corporation (BLCO) Tops Q2 EPS by 1c ; Offers Guidance
-
RBC Capital on Bausch & Lomb Corp. (BLCO): 'FX Likely a Tailwind'
-
Stifel Reiterates Hold Rating on Bausch & Lomb Corp. (BLCO)
-
Bausch + Lomb Corporation (BLCO) Prices Upsized EUR 675M Notes Offering
-
Bausch + Lomb Corporation (BLCO) Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $16 at Barclays
-
Bausch + Lomb Corporation (BLCO) Launches Blink Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the US
-
Bausch + Lomb Corporation (BLCO) announces AGM voting results
-
Bausch + Lomb Corporation (BLCO) Launches Zenlens CHROMA HOA in the U.S.
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $15 at H.C. Wainwright
-
Bausch + Lomb Corporation (BLCO) Misses Q1 EPS by 9c; raises guidance
-
Wells Fargo Reiterates Equal Weight Rating on Bausch & Lomb Corp. (BLCO)
-
Bausch + Lomb Corporation (BLCO) Returning enVista Intraocular Lenses to Market Following Voluntary Recall
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $17 at RBC Capital on Revised Estimates
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $15 at Stifel
-
Wells Fargo Downgrades Bausch & Lomb Corp. (BLCO) to Equal Weight
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $18 at Morgan Stanley
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $20 at H.C. Wainwright
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $17 at BofA Securities
-
Bausch & Lomb Corp. (BLCO) PT Lowered to $17 at JPMorgan
-
Bausch + Lomb Corporation (BLCO) Tops Q4 EPS by 1c; offers guidance
-
H.C. Wainwright Reiterates Buy Rating on Bausch & Lomb Corp. (BLCO)
-
Bausch Health Provides Update on Strategic Alternatives
-
Bausch + Lomb (BLCO) Provides Update on Potential Sale
-
Bausch + Lomb Corporation (BLCO) Acquires Whitecap Biosciences
-
Jefferies Reiterates Buy Rating on Bausch & Lomb Corp. (BLCO), 'Undervalued asset'
-
Bausch + Lomb Corporation (BLCO) Board authorizes management to explore potential sale
-
H.C. Wainwright Reiterates Buy Rating on Bausch & Lomb Corp. (BLCO)
-
BofA Securities Resumes Bausch & Lomb Corp. (BLCO) at Underperform
-
Bausch + Lomb Corporation (BLCO) Acquires Elios Vision
-
Citi Downgrades Bausch & Lomb Corp. (BLCO) to Neutral
-
Morgan Stanley Downgrades Bausch & Lomb Corp. (BLCO) to Equalweight
-
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at H.C. Wainwright
-
Stifel Reiterates Hold Rating on Bausch & Lomb Corp. (BLCO)
-
Bausch + Lomb Corporation (BLCO) Misses Q3 EPS by 3c; raises guidance
-
Bausch & Lomb Corp. (BLCO) PT Raised to $23 at RBC Capital

